Short-Term Shareholder Value Boost From Cardio3’s CorQuest Buy
Executive Summary
Cardio3 BioSciences believes that income in the “several hundred million euros” range could eventually result from its purchase of US company CorQuest Medical’s minimally invasive cardiac surgery technologies, but the acquisition will first and foremost allow the Belgian company to make major strides in creating short-term value for shareholders.